Menu
image description

Category: Therapeutics

A Promising New Therapy

April, 2019 As our name implies, the Lupus Research Alliance aims to forge partnerships and bring other players  to the table to better understand and treat lupus — and our latest venture holds the promise of a new therapy. We — and our affiliate, Lupus Therapeutics — are about to collaborate with Takeda Pharmaceutical Company […] Read More

Lupus Therapeutics Expands Collaboration with Bristol-Myers Squibb to Test Potential Treatment for Lupus

New York, NY– June 27, 2019.  The Lupus Research Alliance (LRA) and its affiliate, Lupus Therapeutics, announced that it has broadened its collaboration with Bristol-Myers Squibb (BMS) to assess the investigational drug BMS-986165 as a potential new therapy for lupus nephritis (LN). This expands the existing collaboration in systemic lupus erythematosus (SLE). Lupus nephritis refers […] Read More

VALUE Study Results Reported at EULAR

MADRID, Spain. June 13, 2019 – Results of the first clinical trial sponsored by the Lupus Research Alliance and conducted through its Lupus Clinical Investigators Network (LuCIN) were presented today at the European Congress of Rheumatology (EULAR) 2019.  Entitled VAlidation in LUpus of an Electronic Patient Reported Outcomes Tool (VALUE), the study showed that a […] Read More

Celebrate Clinical Trials Day May 20!

May 20, 2019 It’s Clinical Trials Day when the Lupus Research Alliance recognizes all the people we support who advance clinical research – scientists who identify and develop potential ways to diagnose, monitor and treat lupus,  researchers who design and conduct the studies to test these methods, and the volunteers who take part in the […] Read More

Benlysta Approved for Children 5-Years and Up

April 26, 2019 We are very pleased to share news from GlaxoSmithKline (GSK) that intravenous Benlysta (belimumab) was approved by the U.S. Food and Drug Administration to treat children with lupus who are five years old or above. The approval was based on data from the ‘PLUTO’ study testing over one year the effectiveness and […] Read More

Lupus Research Alliance and Lupus Therapeutics Partner on New Phase 3 Trial Testing Potential Benefit of Ustekinumab (Stelara®) in Lupus

February 1, 2019 The Lupus Research Alliance announced that its affiliate Lupus Therapeutics is working with the pharmaceutical company, Janssen, to help conduct a Phase 3 trial to evaluate whether their drug ustekinumab (Stelara®) may offer benefit to people with lupus.  Called LOTUS, the international study is being conducted in over 200 sites, 20 of […] Read More

Stelara® and Olumiant® Considered Promising by Lupus Expert

February 19, 2019 In Healio Rheumatology, Dr. Gregg Silverman, professor of medicine and pathology at NYU School of Medicine, provided an overview of potential lupus therapies in development.  He highlighted ustekinumab (brand name Stelara®) and baricitinib (brand name Olumiant®) as two drugs that look particularly promising. “The phase 2 extra-renal trial of baricitinib looks good; […] Read More